Open Access

[Retracted] miR‑222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma

  • Authors:
    • Kai Liu
    • Songyang Liu
    • Wei Zhang
    • Bai Ji
    • Yingchao Wang
    • Yahui Liu
  • View Affiliations

  • Published online on: November 1, 2021     https://doi.org/10.3892/ijo.2021.5280
  • Article Number: 100
  • Copyright : © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Article

Int J Oncol 45: [Related article:] 1537-1546, 2014; DOI: 10.3892/ijo.2014.2577

Following the publication of this paper, it was drawn to the Editors' attention by a concerned reader that the flow cytometric data in Fig. 3A and western blotting data featured in Figs. 3C and 7 were strikingly similar to data appearing in different form in other articles that shared some of the same authors. Owing to the fact that the contentious data in the above article were already under consideration for publication, or had already been published, elsewhere prior to its submission to International Journal of Oncology, the Editor has decided that this paper should be retracted from the Journal. After having been in contact with the authors, they agreed with the decision to retract the paper. The Editor apologizes to the readership for any inconvenience caused.

Related Articles

Journal Cover

December-2021
Volume 59 Issue 6

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Liu K, Liu S, Zhang W, Ji B, Wang Y and Liu Y: [Retracted] miR‑222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma. Int J Oncol 59: 100, 2021
APA
Liu, K., Liu, S., Zhang, W., Ji, B., Wang, Y., & Liu, Y. (2021). [Retracted] miR‑222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma. International Journal of Oncology, 59, 100. https://doi.org/10.3892/ijo.2021.5280
MLA
Liu, K., Liu, S., Zhang, W., Ji, B., Wang, Y., Liu, Y."[Retracted] miR‑222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma". International Journal of Oncology 59.6 (2021): 100.
Chicago
Liu, K., Liu, S., Zhang, W., Ji, B., Wang, Y., Liu, Y."[Retracted] miR‑222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma". International Journal of Oncology 59, no. 6 (2021): 100. https://doi.org/10.3892/ijo.2021.5280